Birelentinib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Birelentinib is an investigational new drug that is being developed by for the treatment of immune thrombocytopenia (ITP), and chronic lymphocytic leukemia. It is a dual Bruton's tyrosine kinase (BTK) and tyrosine-protein kinase Lyn inhibitor.
Birelentinib is an investigational new drug that is being developed by for the treatment of immune thrombocytopenia (ITP), and chronic lymphocytic leukemia. It is a dual Bruton's tyrosine kinase (BTK) and tyrosine-protein kinase Lyn inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370065039 under CC BY-SA 4.0; modifications have been made.